Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 16Lymphoma, Large B-Cell, Diffuse 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Follicular 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Lymphoma 4Wilms Tumor 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Down Syndrome 3Plasmablastic Lymphoma 2Medulloblastoma 2Lymphoproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Ganglioneuroblastoma 2Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdoid Tumor 1Osteosarcoma 1Neuroblastoma 1Multi-centric Castleman's Disease 1Malignant mesenchymal tumor 1Macular dystrophy, corneal type 1 1

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Vincristine × 30 days × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡